GeneNews employs advanced diagnostic technologies aimed at early cancer detection and prevention, significantly impacting healthcare costs. One of their key innovations is the ARISTOTLE® blood test, which can identify molecular signatures of multiple cancers from a single blood sample. This test is designed to detect nine specific types of cancer, including breast, ovarian, and colorectal cancers, with high sensitivity and specificity. The underlying technology, known as The Sentinel Principle, has been validated through extensive patient studies, demonstrating its effectiveness in identifying cancer at earlier stages when treatment outcomes are generally more favorable and costs are lower.

In addition to early detection, GeneNews offers the AVRT™ program, which focuses on cancer prevention by identifying modifiable risk factors associated with cancer development. This program assesses inflammatory and metabolic pathways that contribute to cancer risk, providing actionable insights for lifestyle modifications. By integrating these advanced diagnostic and preventive strategies, GeneNews aims to improve patient outcomes and reduce the financial burden of cancer treatment on healthcare systems. Their commitment to excellence is further underscored by their laboratory's certifications, ensuring high-quality testing and patient care.

Canada

StageZero Life Sciences, Inc. is a national clinical reference lab specializing in personalized blood-based testing to find, understand, and provide key information to help guide treatment decisions.  Our mission is to provide a comprehensive menu of traditional and advanced clinical evidence-based blood tests that aid in early cancer detection.

GeneNews

Company Details